CD274 and Cholecystitis: Atezolizumab, an anti-PD-L1 drug, showed the highest signal strength for spontaneous bacterial peritonitis (ROR = 43.71; 95% CI: 19.14–99.83) (Figure 2C) and cholecystitis (ROR = 5.67; 95% CI: 4.20–7.65) (Figure 3B).